Tag: Revance

All

Game On: Revance Therapeutics Initiates Phase 3 Trial of Topical Botox

Will Revance's RT001 be the first topically neurotoxin treatment?

All

Crown Laboratories Acquires Revance Therapeutics, Expanding Aesthetic Portfolio

The deal expands Crown’s presence in the aesthetics market, bringing Daxxify and the RHA Collection into its portfolio.

Studies Show Efficacy of Daxxify to Treat Frown Lines
AbbVie’s Botox Patent Lawsuit is ‘Very Unlikely to Derail’ Revance’s Rival Launch: Analysts
Revance Presents DaxibotulinumtoxinA for Injection and RHA Collection Data at the ASDS Virtual Annual Meeting
Revance Plans to Introduce Its Aesthetic Portfolio in September
Studies of DaxibotulinumtoxinA Injection to Treat Forehead Lines and Crow’s Feet Produce Positive Results, Revance Announces
Revance and Mylan to Advance Development Program for Biosimilar to BOTOX

All

New Approach Could Help Prevent Scarring After Surgery

Researchers have discovered a naturally occurring protein that could lead to new therapies for preventing excessive scarring in patients during wound healing.

Revance Therapeutics Inc Announces Study Results and a License Agreement for RT002

by Debbie Overman | Dec 6, 2018 | Aesthetics, Body Makeover | 0

Revance Therapeutics Inc, a Newark, Calif-based developer of neuromodulators for the treatment of aesthetic and therapeutic conditions, announces two pieces of company news regarding RT002.

Hot Stuff: November 2015

by Debbie Overman | Oct 28, 2015 | Sculpting | 0

JUVEDERM ULTRA XC for lips and Coolscupting’s new Coolmini for the double chin are among November’s “Hot Stuff.”

Tag: Revance

All

Game On: Revance Therapeutics Initiates Phase 3 Trial of Topical Botox

Cosmetic Surgery Foundation Welcomes New Members to Industry Advisory Council

The Face: It’s Faux Tox Time

Revance Relocates from California to Tennessee

Long Shot: Revance’s RT002 May Banish Frown Lines for 7 Months

Aji Bio-Pharma and Revance in Manufacturing Deal for Anti-Wrinkle Rival to Botox

Hot Stuff: February 2015

Revance Therapeutics Provides Update on DaxibotulinumtoxinA for Injection Pre-Approval Inspection

As Revance Nears a Potential Launch for its Botox Rival, AbbVie Sues for Patent Infringement

All

Crown Laboratories Acquires Revance Therapeutics, Expanding Aesthetic Portfolio

Studies Show Efficacy of Daxxify to Treat Frown Lines

AbbVie’s Botox Patent Lawsuit is ‘Very Unlikely to Derail’ Revance’s Rival Launch: Analysts

Revance Presents DaxibotulinumtoxinA for Injection and RHA Collection Data at the ASDS Virtual Annual Meeting

Revance Plans to Introduce Its Aesthetic Portfolio in September

Studies of DaxibotulinumtoxinA Injection to Treat Forehead Lines and Crow’s Feet Produce Positive Results, Revance Announces

Revance and Mylan to Advance Development Program for Biosimilar to BOTOX

All

New Approach Could Help Prevent Scarring After Surgery

Integrating GLP-1s into Aesthetic Practice: Dr Johnny Franco on Personalizing the Patient Journey

New Revanesse Renew+ Skin-boosting Injection Debuts in Canada

Half of Americans Worry About Skin Aging, But Many Still Skip Sunscreen

Revance Therapeutics Inc Announces Study Results and a License Agreement for RT002

Hot Stuff: November 2015

Plastic Surgery Practice

Our Parent Company

Key Resources

Helpful Links